Clinical Trials Search
Clinical Trial 19394
Study Type: Treatment
Phase of Study: Pilot
- Heather Han
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
The purpose of this research study is to: · Test how safe Niraparib (Study Drug) is and how well it works.
Primary: To evaluate the preliminary antitumor activity of niraparib assessed as the tumor response rate based on the change in tumor volume as measured by breast MRI, observed after treatment with niraparib in the neoadjuvant treatment of localized, human epidermal growth factor receptor 2 (HER2)-negative, breast cancer susceptibility gene (BRCA) mutant (BRCAmut) breast cancer patients.